Negotiations over another round of COVID-19 legislation are on pause as Members of Congress wait on final election results. Talks are expected to resume once Congress to returns to Washington-the Senate is slated to resume business on November 9, while the House will return on November 16. At minimum, Congress will have to pass legislation to keep the government funded past the December 11 deadline.
Access to 340B Medications at Risk
The 340B Drug Pricing Program is a critical program for health center patients, ensuring that they can obtain medications at affordable prices. Recently, several threats to the program have emerged that endanger the intended purpose of the 340B program and health centers’ ability to provide care to their patients. NACHC, Primary Care Associations, and community health centers across the country are talking with Members of Congress and HRSA, urging action to stop these damaging provisions from going into effect.
TPCA Engagement on 340B
- TPCA sent a letter to Tennessee's Attorney General outlining 340B developments and requesting that Attorney General Slatery collaborate with the Connecticut Attorney General, who is working with AGs across the country to address actions from drug manufacturers.
- TPCA submitted comments to the proposed rule to implement President Trump’s Executive Order on Insulin and EpiPens.
TPCA submitted suggested improvements to the 340B program in response to a public information request from Senator Alexander and Congressman Walden.
- TPCA requested Tennessee’s members of the House of Representatives support for a bi-partisan letter to HHS expressing concerns about Kalderos’ recent actions to shift the 340B program to a rebate model.
NACHC Lawsuit Against HHS
NACHC filed a lawsuit against the Department of Health and Human Services (HHS) to compel HHS to implement a dispute resolution process for the 340B program that would allow health centers to take action against drug manufacturers for halting the shipment of 340B priced drugs to contract pharmacies.